One of the peptides, provided with a cyclic arrangement and a disulfide bridge (i.e., gD(1–36)(K10C-T29C)), was considered the best candidate to block BTLA inhibitory function and increase the immune response towards cancer cells [164]. Here, BTLA is linked to cancer.